Company Overview: Bioline RX Ltd.


Industry News

1 Jun

BioLineRx Reports Regulatory Submissions of Three Phase 1b Trials for BL-8040 in Combination With Atezolizumab for Solid Tumors

BioLineRx Ltd. (NASDAQ: BLRX, TASE:BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that Genentech, a member of the Roche Group, has filed a total of three regulatory submissions required to commence Phase 1b trials for BL-8040 in combination with atezolizumab (Tecentriq®), Genentech’s anti-PDL1 cancer immunotherapy,...

Read more

25 May

BioLineRx Reports First Quarter 2017 Financial Results

TEL AVIV, Israel, May 25, 2017 /PRNewswire/ — BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for the first quarter ended March 31, 2017. Highlights and achievements during the first quarter 2017 and to date: Continued advancing the Company’s lead...

Read more

16 May

BioLineRx to Report First Quarter 2017 Results on May 25, 2017

TEL AVIV, Israel, May 16, 2017 /PRNewswire/ — BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will release its unaudited financial results for the quarter ended March 31, 2017 on Thursday, May 25, 2017, before the US markets open. The Company will...

Read more

3 May

BioLineRx to Initiate Phase 3 Study with BL-8040 as Novel Stem Cell Mobilization Treatment Following Successful Meeting with FDA

TEL AVIV, Israel, May 3, 2017 /PRNewswire/ — – Initiation of Phase 3 registrational study expected in second half of this year – Study to focus on stem cell mobilization for autologous transplantation in multiple myeloma patients BioLineRx Ltd. (NASDAQ/TASE: BLRX, BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and...

Read more

31 Mar

BioLineRx Prices $25 Million Underwritten Public Offering

TEL AVIV, Israel, March 31, 2017 /PRNewswire/ — BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical stage biopharmaceutical development company focused on oncology and immunology, today announced that it has priced an underwritten public offering of approximately 29.4 million American Depositary Shares (“ADSs”), each representing one (1) of its ordinary shares,...

Read more

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address